Participated · Series C · Jul 2026

AIsphere develops multimodal video large models and related products, including the consumer-facing PixVerse (for overseas markets) and PaiWo AI (for domestic users). The company launched its real-time world model PixVerse R1 in January 2026, which supports 1080p real-time generation and on-the-fly video edits via natural language, and released PixVerse Game in July 2026 to apply real-time video generation to interactive entertainment. AIsphere reports that PixVerse has accumulated over 150 million global users and its PixVerse V6 model ranks on international benchmarks for text-to-video and image-to-video. Commercial partnerships and pilots include collaborations with Mango Media and enterprise partners such as Alibaba, Giant Group, China Ruiyi, BlueFocus and 37 Interactive Entertainment across short drama, animation, variety, promotional assets, interactive games and multilingual content. Financially, the company has completed multiple financings since its 2023 founding, including a March 2026 $300M C round that valued the company at $1.0B, and most recently the ¥2.98B C+ tranche led by Alibaba to fund further R&D and global expansion.

Participated · Series C · Jul 2026

PixVerse develops generative video models including a V-Series for consumer/API use, a C-Series for professional film and commercial workflows, and an R-Series of world models for game development and world building. Its tool can generate videos up to 4K resolution with audio baked in, and the company reports over 150 million registered users and more than 15 million monthly active users. The startup offers image-to-video generation at a cited competitive rate of $4.80 per minute. PixVerse released its R-Series world models earlier this year and plans to launch a new V-Series model and a new world-model version within the year. The company has about 150 employees across offices in Singapore, Beijing, and Shanghai and has commercial relationships including a deployment deal with investor Alibaba.

Participated · Series B · Jun 2024

Xingluo Intelligent focuses on building integrated intelligent unmanned aerial systems that combine autonomous flight, autonomous charging and data processing. The company has independently developed drone charging hangars and autonomous flight systems that are compatible with multiple industry models. Its systems enable automatic takeoff, autonomous cruising, automated detection, automatic return-to-nest and data analysis. Xingluo is described as a leading company in the drone intelligence niche market. The company recently completed a B round financing of more than ¥100 million. The raise was reported by IT Juzi.

Participated · Series A · Jan 2022

Mauna Kea Semiconductors (MKSemi) designs low-power ultra-wideband (UWB) system-on-chip products to enable high-precision ranging and location for IoT and consumer devices. The company launched the MK8000 SoC, which it describes as the world’s lowest-power, highest-integrated UWB chip and is now available to partners and customers. MK8000 is promoted for ultra-low power consumption (reported 43mA@3V in RX), the widest frequency band, a high level of integration to lower BOM, and an intelligent signal processor that improves compute efficiency roughly 10x. MKSemi says the chip enables tiny-battery devices and accelerates OEM/ODM deployment of location and direction-finding solutions. The company is partnering with Infineon Technologies and ThinkSeed Systems to combine MK8000 with Infineon’s Bluetooth LE MCU and to qualify designs for industrial and automotive markets. Management states the technology is already being integrated with tier-one smartphone OEMs and targets smart homes, cities, automobiles, wearables and health monitoring use cases amid a rapidly growing UWB market.

Participated · Equity · Sep 2020

Taimei Technology develops TrialOS, a platform that connects hospitals, drug makers, regulators, and patients across clinical research workflows. TrialOS comprises more than 20 applications managing clinical research projects, trial documents, patient data, and an adverse drug reaction alerting system. The company says TrialOS supports one third of registered clinical research in China and one fifth of adverse drug reaction submissions. Taimei also offers software to help drug firms with marketing and regulatory licensing. The company disclosed it raised RMB 1.2 billion (USD 176 million) in a recent financing round.